Understanding the tumor-promoting mechanisms and cellular and molecular targets of IFNγ in ovarian cancer is crucial for minimizing its tumor-promoting functions in PD-1/PD-L1-blocking cancer immunotherapies that induce IFNγ expression and in other therapies associated with IFNγ release. This evidence concerns the gene IFNG and cancer.